Convalescent Plasma for the Treatment of Severe COVID-19

References

• Schoeman D, Fielding BC. Coronavirus envelope protein: current knowledge. Virol J. 2019;16:69.
   PubMed Web of Science ®Google Scholar
• Chen Y, Liu Q, Guo D. Coronaviruses: genome structure, replication, and pathogenesis. J Med Virol. 2020;92:418–423. doi:10.1002/jmv.25681
   PubMed Web of Science ®Google Scholar
• Kuiken T, Fouchier RA, Schutten M, et al. Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome. Lancet. 2003;362(9380):263–270. doi:10.1016/S0140-6736(03)13967-0
   PubMed Web of Science ®Google Scholar
• Drosten C, Günther S, Preiser W, et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med. 2003;348(20):1967–1976. doi:10.1056/NEJMoa030747
   PubMed Web of Science ®Google Scholar
• de Groot RJ, Baker SC, Baric RS, et al. Commentary: middle east respiratory syndrome coronavirus (MERS-CoV): announcement of the Coronavirus Study Group. J Virol. 2013;87(14):7790–7792. doi:10.1128/JVI.01244-13
   PubMed Web of Science ®Google Scholar
• World Health Organization. Coronavirus disease (COVID-19) pandemic. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019. Accessed November 10, 2020.
   Google Scholar
• Mahase E. Covid-19: WHO declares pandemic because of “alarming levels” of spread, severity, and inaction. BMJ. 2020;368:m1036. doi:10.1136/bmj.m1036
   PubMed Web of Science ®Google Scholar
• Lyngbakken MN, Berdal JE, Eskesen A, et al. A pragmatic randomized controlled trial reports lack of efficacy of hydroxychloroquine on coronavirus disease 2019 viral kinetics. Nat Commun. 2020;11(1):5284. doi:10.1038/s41467-020-19056-6
   PubMed Web of Science ®Google Scholar
• Wang Y, Zhang D, Du G, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020;395(10236):1569–1578. doi:10.1016/S0140-6736(20)31022-9
   PubMed Web of Science ®Google Scholar
• WHO Solidarity trial consortium. Repurposed antiviral drugs for COVID-19 –interim WHO SOLIDARITY trial results. medRxiv. 2020. doi:10.1101/2020.10.15.20209817
   Google Scholar
• Shen C, Wang Z, Zhao F, et al. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. JAMA. 2020;323(16):1582–1589. doi:10.1001/jama.2020.4783
   PubMed Web of Science ®Google Scholar
• Casadevall A, Dadachova E, Pirofski L. Passive antibody therapy for infectious diseases. Nat Microbiol Rev. 2004;2:695–703. doi:10.1038/nrmicro974
   PubMed Web of Science ®Google Scholar
• Luke TC, Casadevall A, Watowich SJ, Hoffman SL, Beigel JH, Burgess TH. Hark back: passive immunotherapy for influenza and other serious infections. Crit Care Med. 2010;38:e66–e73. doi:10.1097/CCM.0b013e3181d44c1e
   PubMed Web of Science ®Google Scholar
• Luke TC, Kilbane EM, Jackson JL, Hoffman SL. Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment? Ann Intern Med. 2006;145:599–609. doi:10.7326/0003-4819-145-8-200610170-00139
   PubMed Web of Science ®Google Scholar
• Mair-Jenkins J, Saavedra-Campos M, Baillie JK, et al. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. J Infect Dis. 2015;211:80–90. doi:10.1093/infdis/jiu396
   PubMed Web of Science ®Google Scholar
• Salazar E, Christensen PA, Graviss EA, et al. Treatment of Coronavirus disease 2019 patients with convalescent plasma reveals a signal of significantly decreased mortality. Am J Pathol. 2020;190(11):2290–2303. doi:10.1016/j.ajpath.2020.08.001
   PubMed Web of Science ®Google Scholar
• Wooding DJ, Bach H. Treatment of COVID-19 with convalescent plasma: lessons from past coronavirus outbreaks. Clin Microbiol Infect. 2020;26(10):1436–1446. doi:10.1016/j.cmi.2020.08.005
   PubMed Web of Science ®Google Scholar
• Stevens RW, Rivera CG, Saleh OA. Time to treat: applying lessons learned from other viral syndromes to SARS-CoV-2. Mayo Clin Proc Innov Qual Outcomes. 2020;4:759–763. doi:10.1016/j.mayocpiqo.2020.09.010.
   Google Scholar
• Rojas M, Rodríguez Y, Monsalve DM, et al. Convalescent plasma in Covid-19: possible mechanisms of action. Autoimmun Rev. 2020;19(7):102554. doi:10.1016/j.autrev.2020.102554
   PubMed Web of Science ®Google Scholar
• Mekonnen D, Mengist HM, Derbie A, et al. Diagnostic accuracy of serological tests and kinetics of severe acute respiratory syndrome coronavirus 2 antibody: a systematic review and meta-analysis. Rev Med Virol. 2020;5:e2181. doi:10.1002/rmv.2181.
   Web of Science ®Google Scholar
• Mazzini L, Martinuzzi D, Hyseni I, et al. Comparative analyses of SARS-CoV-2 binding (IgG, IgM, IgA) and neutralizing antibodies from human serum samples. J Immunol Methods. 2020;27:112937.
   Google Scholar
• Padoan A, Bonfante F, Pagliari M, et al. Analytical and clinical performances of five immunoassays for the detection of SARS-CoV-2 antibodies in comparison with neutralization activity. EbioMedicine. 2020;62:103101. doi:10.1016/j.ebiom.2020.103101
   PubMed Web of Science ®Google Scholar
• Bal A, Pozzetto B, Trabaud M-A, et al. Evaluation of high-throughput SARS-CoV-2 serological assays in a longitudinal cohort of mild COVID-19 patients: sensitivity, specificity and association with virus neutralization test. medRxiv. 2020. doi:10.1101/2020.09.30.20194290
   Google Scholar
• Hoiland RL, Fergusson NA, Mitra AR, et al. The association of ABO blood group with indices of disease severity and multiorgan dysfunction in COVID-19. Blood Adv. 2020;4(20):4981–4989. doi:10.1182/bloodadvances.2020002623
   PubMed Web of Science ®Google Scholar
• Barnkob MB, Pottegård A, Støvring H, et al. Reduced prevalence of SARS-CoV-2 infection in ABO blood group O. Blood Adv. 2020;4(20):4990–4993. doi:10.1182/bloodadvances.2020002657
   PubMed Web of Science ®Google Scholar
• Golinelli D, Boetto E, Maietti E, Fantini MP, Suppiah V. The association between ABO blood group and SARS-CoV-2 infection: a meta-analysis. PLoS One. 2020;15(9):e0239508. doi:10.1371/journal.pone.0239508
   Web of Science ®Google Scholar
• Franchini M, Glingani C, Del Fante C, et al. The protective effect of O blood type against SARS-CoV-2 infection. Vox Sang. 2020. doi:10.1111/vox.13003
   Web of Science ®Google Scholar
• Duan K, Liu B, Li C, et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci U S A. 2020;117(17):9490–9496. doi:10.1073/pnas.2004168117
   PubMed Web of Science ®Google Scholar
• Perotti C, Baldanti F, Bruno R, et al. Covid-19 plasma task force. Mortality reduction in 46 severe COVID-19 patients treated with hyperimmune plasma. A proof of concept single arm multicenter trial. Haematologica. 2020;105:2834–2840. doi:10.3324/haematol.2020.261784
   PubMed Web of Science ®Google Scholar
• Franchini M. Why should we use convalescent plasma for COVID-19? Eur J Intern Med. 2020;77:150–151. doi:10.1016/j.ejim.2020.05.019
   Web of Science ®Google Scholar
• Liu STH, Lin HM, Baine I, et al. Convalescent plasma treatment of severe COVID-19: a propensity score-matched control study. Nat Med. 2020;26:1708–1713. doi:10.1038/s41591-020-1088-9.
   PubMed Web of Science ®Google Scholar
• Salazar E, Christensen PA, Graviss EA, et al. Significantly decreased mortality in a large cohort of coronavirus disease 2019 (COVID-19) patients transfused early with convalescent plasma containing high-titer anti-severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) spike protein IgG. Am J Pathol. 2021;191(1):90–107. doi:10.1016/j.ajpath.2020.10.008
   PubMed Web of Science ®Google Scholar
• Xia X, Li K, Wu L, et al. Improved clinical symptoms and mortality among patients with severe or critical COVID-19 after convalescent plasma transfusion. Blood. 2020;136(6):755–759. doi:10.1182/blood.2020007079
   PubMed Web of Science ®Google Scholar
• Rogers R, Shehadeh F, Mylona EK, et al. Convalescent plasma for patients with severe COVID-19: a matched cohort study. Clin Infect Dis. 2020;ciaa1548. Doi:10.1093/cid/ciaa1548
   Web of Science ®Google Scholar
• Ibrahim D, Dulipsingh L, Zapatka L, et al. Factors associated with good patient outcomes following convalescent plasma in COVID-19: a prospective Phase II clinical trial. Infect Dis Ther. 2020;20:1–14.
   Google Scholar
• Abolghasemi H, Eshghi P, Cheraghali AM, et al. Clinical efficacy of convalescent plasma for treatment of COVID-19 infections: results of a multicenter clinical study. Transfus Apher Sci. 2020;59:102875. doi:10.1016/j.transci.2020.102875
   PubMed Web of Science ®Google Scholar
• Joyner MJ, Bruno KA, Klassen SA, et al. Safety update: COVID-19 convalescent plasma in 20,000 hospitalized patients. Mayo Clin Proc. 2020;95(9):1888–1897. doi:10.1016/j.mayocp.2020.06.028
   PubMed Web of Science ®Google Scholar
• Li L, Zhang W, Hu Y, et al. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial. JAMA. 2020;324(5):460–470. doi:10.1001/jama.2020.10044
   PubMed Web of Science ®Google Scholar
• Agarwal A, Mukherjee A, Kumar G, Chatterjee P, Bhatnagar T, Malhotra P; PLACID Trial Collaborators. Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial). BMJ. 2020;371:m3939. doi:10.1136/bmj.m3939
   PubMed Web of Science ®Google Scholar
• Gharbharan A, Jordans CCE, Geurtsvankessel C, et al. Convalescent plasma for COVID-19. A randomized trial. medRxiv. 2020.
   Google Scholar
• Rasheed AM, Fatak DF, Hashim HA, et al. The therapeutic potential of convalescent plasma therapy on treating critically-ill COVID-19 patients residing in respiratory care units in hospitals in Baghdad, Iraq. Infez Med. 2020;28(3):357–366.
   Google Scholar
• Avendano-Sola C, Ramos-Martinez A, Munez-Rubio E, et al. Convalescent plasma for COVID-19: a multicenter, randomized clinical trial. medRxiv. 2020.
   Google Scholar
• Simonovich VA, Burgos Pratx LD, Scibona P, et al. PlasmAr Study Group. A randomized trial of convalescent plasma in Covid-19 severe pneumonia. N Engl J Med. 2020. doi:10.1056/NEJMoa2031304
   PubMed Web of Science ®Google Scholar
• Rajendran K, Krishnasamy N, Rangarajan J, Rathinam J, Natarajan M, Ramachandran A. Convalescent plasma transfusion for the treatment of COVID-19: systematic review. J Med Virol. 2020;92:1475–1483. doi:10.1002/jmv.25961
   PubMed Web of Science ®Google Scholar
• Bakhtawar N, Usman M, Khan MMU. Convalescent plasma therapy and its effects on COVID-19 patient outcomes: a systematic review of current literature. Cureus. 2020;12(8):e9535.
   Web of Science ®Google Scholar
• Sarkar S, Soni KD, Khanna P. Convalescent plasma is a clutch at straws in COVID-19 management! A systematic review and meta-analysis. J Med Virol. 2020.
   Google Scholar
• Rabelo-da-Ponte FD, Silvello D, Scherer JN, Ayala AR, Klamt F. Convalescent plasma therapy in patients with severe or life-threatening COVID-19: a metadata analysis. J Infect Dis. 2020;222(9):1575–1578. doi:10.1093/infdis/jiaa509
   PubMed Web of Science ®Google Scholar
• Talaie H, Hosseini SM, Nazari M, et al. Is there any potential management against COVID-19? A systematic review and meta-analysis. Daru. 2020;28:1–13. doi:10.1007/s40199-020-00367-4.
   Web of Science ®Google Scholar
• Wang M, Wu T, Zuo Z, et al. Evaluation of current medical approaches for COVID-19: a systematic review and meta-analysis. BMJ Support Palliat Care. 2020;bmjspcare-2020-002554. Doi:10.1136/bmjspcare-2020-002554.
   Web of Science ®Google Scholar
• Juul S, Nielsen EE, Feinberg J, et al. Interventions for treatment of COVID-19: a living systematic review with meta-analyses and trial sequential analyses (The LIVING Project). PLoS Med. 2020;17(9):e1003293. doi:10.1371/journal.pmed.1003293
   Web of Science ®Google Scholar
• Klassen SA, Senefeld JW, Johnson PW, et al. Evidence favoring the efficacy of convalescent plasma for COVID-19 therapy. medRxiv. 2020. doi:10.1101/2020.07.29.20162917.
   Google Scholar
• Chai KL, Valk SJ, Piechotta V, et al. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review. Cochrane Database Syst Rev. 2020;10:CD013600. doi:10.1002/14651858.CD013600.pub3
   PubMed Web of Science ®Google Scholar